{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:49:12Z","timestamp":1790668152103,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T00:00:00Z","timestamp":1679184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020141","name":"Akebia Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jacl.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T04:50:35Z","timestamp":1679460635000},"page":"342-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5195-6614","authenticated-orcid":false,"given":"Joseph L.","family":"Witztum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-1636","authenticated-orcid":false,"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9555-6260","authenticated-orcid":false,"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnetta","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2023.03.007_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2023.03.007_bib0002","series-title":"GeneReviews","article-title":"Familial lipoprotein lipase deficiency\uff0e","author":"Burnett","year":"1999"},{"issue":"9","key":"10.1016\/j.jacl.2023.03.007_bib0003","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jacl.2023.03.007_bib0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","article-title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia","volume":"272","author":"Surendran","year":"2012","journal-title":"J Intern Med"},{"issue":"17","key":"10.1016\/j.jacl.2023.03.007_bib0005","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1611930","article-title":"Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia","volume":"376","author":"Beigneux","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacl.2023.03.007_bib0006","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacl.2023.03.007_bib0007","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.jacl.2023.03.007_bib0008","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2337\/diacare.4.3.343","article-title":"Chylomicronemia syndrome in diabetes mellitus","volume":"4","author":"Chait","year":"1981","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.jacl.2023.03.007_bib0009","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"11","key":"10.1016\/j.jacl.2023.03.007_bib0010","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.jacl.2023.03.007_bib0011","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci"},{"issue":"23","key":"10.1016\/j.jacl.2023.03.007_bib0012","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2023.03.007_bib0013","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2023.03.007_bib0014","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.jval.2018.09.2771","article-title":"Limitations of the EQ5D instrument in the assessment of quality of life in chronic rare diseases: a case study from FCS [abstract PSY197]","volume":"21","author":"Priedane","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jacl.2023.03.007_bib0015","unstructured":"Waylivra [summary of product characteristics]. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/waylivra-epar-product-information_en.pdf. Accessed March 13, 2023."},{"key":"10.1016\/j.jacl.2023.03.007_bib0016","unstructured":"Familial chylomicronemia syndrome. 2021. https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=444490. Accessed March 28, 2023."},{"issue":"33","key":"10.1016\/j.jacl.2023.03.007_bib0017","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-Acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.jacl.2023.03.007_bib0018","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"}],"updated-by":[{"DOI":"10.1016\/j.jacl.2023.09.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000}}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742300065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742300065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T10:23:07Z","timestamp":1697278987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742300065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S193328742300065X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2023.03.007","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jacl.2023.09.010","asserted-by":"object"}]},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 National Lipid Association.","name":"copyright","label":"Copyright"}]}}